GlassScriptPhysician profile
Marie L Borum
NPI 1487616397
$42,273.80
in general payments reported to CMS, 2019-2025
28 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.50 · 2020: $33.73 · 2021: $4,392 · 2022: $13K · 2023: $17K · 2024: $5,797 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $3,472 · Travel and Lodging: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,431.50 |
| Food and Beverage | $3,472.17 |
| Travel and Lodging | $1,436.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36,932.12 | 2021-2025 | Entyvio, Gattex |
| Exact Sciences Corporation | $1,417.83 | 2024-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $755.60 | 2022-2025 | Tremfya, Stelara |
| Abbvie INC. | $641.95 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Scientific Affairs, LLC | $411.82 | 2022-2025 | Tremfya, Stelara |
| Pentax of America, INC. | $401.70 | 2023-2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Phathom Pharmaceuticals, INC. | $289.64 | 2024-2025 | Voquezna |
| Genzyme Corporation | $259.04 | 2022-2025 | |
| Celgene Corporation | $238.21 | 2022-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $121.41 | 2022 | |
| Viiv Healthcare Company | $118.81 | 2025 | Apretude, Cabenuva |
| Pfizer INC. | $118.32 | 2022-2024 | |
| Enterra Medical, INC. | $117.63 | 2024 | |
| Medtronic, INC. | $101.41 | 2022 | |
| Boston Scientific Corporation | $60.36 | 2020-2025 | Endoarmor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $39.22 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $34.06 | 2022-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $27.41 | 2025 | Terlivaz |
| W. L. Gore & Associates, INC. | $23.21 | 2023 | Gore Cardioform Septal Occluder |
| Organon LLC | $22.32 | 2023 | Hadlima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.25 | 2022 | |
| Novo Nordisk INC | $21.94 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $19.91 | 2024 | Rebyota |
| Braintree Laboratories, INC. | $18.50 | 2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $17.59 | 2024 | Resmetirom |
| Allergan, INC. | $15.08 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.42 | 2019 | |
| Gilead Sciences, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Borum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.